Navigation Links
American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide
Date:10/5/2007

ATLANTAOctober 04, 2007 The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 109 national research and training grants totaling more than $52.6 million in the first of two grant cycles for 2008. Of the grants, 91 are new and 18 are renewals of previous grants. All of the grants go into effect January 1, 2008.

The American Cancer Societys Research and Training Program has funded 40 Nobel Prize laureates since its inception in 1946, during which time it has invested about $3.1 billion in cancer research, much of that focusing on the work of promising new investigators. The Society currently funds 938 multi-year grants totaling over $457 million. Among the newly awarded grants approved for funding:

  • Katherine Crew, MD of Columbia University in New York, N.Y. is examining the role of green tea extracts to possibly lower the risk of ER-negative breast cancer, a form of breast cancer which is often found in younger women and associated with a poorer prognosis.

  • Prasak Jallepalli, MD, PhD of Memorial Sloan-Kettering Cancer Center in New York. N.Y. is investigating a new function for the protein, Polo kinase, which is higly overexpressed in many cancers and can turn on major cell division pathways at exactly the right time and right place.

  • Nomeli Nunez, PhD of the University of Texas, Austin is working on understanding the relationship in post-menopausal women between obesity and an increase in breast cancer.

  • Adam Marcus, PhD of Emory University in Atlanta, Ga. is studying how non-small cell lung cancer takes on aggressive metastatic characteristics and how a particular tumor suppressor, named LKB1, plays a role when it triggers the front part of a cell to become indistinguishable from the end.

  • Sara Higgins, PhD of Mount Sinai School of Medicine, New York, N.Y. focuse
    '/>"/>

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Abstain from sex- the latest mantra of American teens
2. Clintons new problem - Is the outgoing American president suffering from skin cancer?
3. American scientists alter gene makeup of babies
4. FDA attacks American Red Cross for blood violations
5. Poll Finds Many Americans Misinformed About Cancer
6. Poll Finds Many Americans Misinformed About Cancer
7. Hypertension Drug of Choice for African Americans
8. 38 million Americans including 14 million children left to combat hunger
9. Americans Consume Far Too Much Salt and Sodium
10. Americans Growing Out Of Shape
11. Rise in Stress among Americans
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 2Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 3Heska Announces Extension of Credit Agreement With Wells Fargo 2Heska Announces Extension of Credit Agreement With Wells Fargo 3Study Shows That Diets of Infants are Improving 3B Concerns Remain for Toddlers and Preschoolers 59710 1Study Shows That Diets of Infants are Improving 3B Concerns Remain for Toddlers and Preschoolers 59710 2Study Shows That Diets of Infants are Improving 3B Concerns Remain for Toddlers and Preschoolers 59710 3Study Shows That Diets of Infants are Improving 3B Concerns Remain for Toddlers and Preschoolers 59710 4Study Shows That Diets of Infants are Improving 3B Concerns Remain for Toddlers and Preschoolers 59710 5Study Shows That Diets of Infants are Improving 3B Concerns Remain for Toddlers and Preschoolers 59710 6Study Shows That Diets of Infants are Improving 3B Concerns Remain for Toddlers and Preschoolers 59710 7Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming 14517 1Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming 14517 2Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming 14517 3New chromosomal abnormality identified in leukemia associated with Down syndrome 10408 1New chromosomal abnormality identified in leukemia associated with Down syndrome 10408 2New chromosomal abnormality identified in leukemia associated with Down syndrome 10408 3